Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.